• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study
Publication date: Available online 5 June 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Mika Kivimäki, Jaana Pentti, Jane E Ferrie, G David Batty, Solja T Nyberg, Markus Jokela, Marianna Virtanen, Lars Alfredsson, Nico Dragano, Eleonor I Fransson, Marcel Goldberg, Anders Knutsson, Markku Koskenvuo, Aki Koskinen, Anne Kouvonen, Ritva Luukkonen, Tuula Oksanen, Reiner Rugulies, Johannes Siegrist, Archana Singh-Manoux, Sakari Suominen, Töres Theorell, Ari Väänänen, Jussi Vahtera, Peter J M Westerholm, Hugo Westerlund, Marie Zins, Timo Strandberg, Andrew Steptoe, John Deanfield Background Although som...
Source: The Lancet Diabetes and Endocrinology - June 6, 2018 Category: Endocrinology Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research